Company: BNBX
Filing Date: 2025-01-10
Form Type: S-1/A
Source: 0001104659-25-002521
Chunk: 13

Company: BNB PLUS CORP.
Filing Date: 2025-01-10
Form: S-1/A
Chunk 13
---
 We anticipate upgrades to GMP Site 1 to enable the manufacture of LineaDNA for use as, or incorporation into,
a biologic, drug substance and/or drug product manufacture to cost less than $1 million. Potential upgrades to GMP Site 1 would not alter
its current footprint within our existing laboratory space. We anticipate that a GMP Site 2 would require us to acquire additional space.

<div align='center'>4</div>

MDx Testing Services

Through Applied DNA Clinical Labs, LLC (“ADCL”),
we leverage our expertise in DNA and RNA detection via PCR to provide and develop clinical molecular diagnostics and genetic (collectively
“MDx”) Testing Services. ADCL is a New York State Department of Health (“NYSDOH”) clinical laboratory improvement
amendments (“CLIA”)-certified laboratory which is currently permitted for virology and genetics (molecular). In providing
MDx Testing Services, ADCL employs its own or third-party molecular diagnostic tests.

We have successfully internally validated our
pharmacogenomics testing services (the “PGx Testing Services”). Our PGx Testing Services utilizes a 120-target PGx panel
test to evaluate the unique genotype of a specific patient to help guide the patient’s healthcare provider in making individual
drug therapy decisions. Our PGx Testing Services are designed to interrogate DNA targets on over 33 genes and provide genotyping information
relevant to certain cardiac, mental health, oncology, and pain management drug therapies.

On June 12, 2024 we received full approval
from NYSDOH for our PGx Testing Services. Recently published studies show that population-scale PGx enabled medication management can
significantly reduce overall population healthcare costs, reduce adverse drug events, and increase overall population wellbeing. These
benefits can result in significant cost savings to large entities and self-insured employers, the latter accounting for approximately
65% of all U.S. employers in 2022.We plan to leverage our PGx Testing Services to provide PGx testing services to large entities, self-insured
employers and healthcare providers, as well as concierge healthcare providers.

On September 11, 2024, we announced that
ADCL has launched an expansion of its clinical testing services for the detection of Mpox (formerly monkeypox) to include testing for
both Mpox Clade I and Clade II. The launch of the expanded Mpox testing service comes after ADCL’s interaction with relevant regulatory
bodies, including the NY